About this trial
Hematopoietic stem cell transplantation is an important therapeutic approach for hematologic malignancies, and the impact of donor age on transplant outcomes remains an active area of investigation. Older donors may be associated with impaired stem cell fitness, delayed immune reconstitution, and reduced T-cell function. However, randomized controlled trials directly comparing transplant outcomes by donor age are difficult to conduct because of ethical constraints, and previous retrospective studies have yielded inconsistent findings due to confounding bias and limited causal interpretability. Target trial emulation (TTE) is a methodological framework that uses observational data to emulate the design principles of a randomized trial, thereby reducing biases such as immortal time bias, time-varying confounding, and prevalent-user bias, and improving the validity of causal inference. Therefore, this study will use a large single-center retrospective clinical cohort to perform a TTE analysis, aiming to approximate the causal framework of an randomized trial and systematically evaluate the effect of donor age on clinical outcomes after allo-HSCT, thereby providing higher-quality evidence to optimize donor selection strategies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older.
Diagnosis of hematologic malignancy.
Underwent first allogeneic hematopoietic stem cell transplantation.
HLA matching level of 0.5 or higher.
Disqualifiers
Previous autologous or allogeneic hematopoietic stem cell transplantation.
HLA matching level below 0.5.
Missing donor age information.
Missing key exposure-defining or outcome-defining data required for the analysis.
Trial population
This study includes adult patients with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation at the study center. Eligible patients will be identified from retrospective clinical records and grouped according to donor age recorded at the time of transplantation.
Trial design
Cohort
Retrospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Overall Survival
Overall survival was defined as the interval between hematopoietic stem cell transplantation and death from any cause.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: